Replies to post #31531 on ViaDerma Inc (VDRM)

[jim992]

Fantastic analytical answer!! Thank you!!

As I read the board each day, I am trying to get a feel for what makes our brethren make the decisions they make, what is of most interest, etc.

With a company like VDRM, I feel understanding the company's investors is part of understanding the company and its ups and downs.

Thank you for taking the time to give such a well thought out answer! I appreciate anyone willing to give the time to contribute to our IHUB knowledge base.

Merry VDRM Christmas to us all! Jim

[zombywolf]

Some other things to consider, as you laid out a view of VDRM with limited risk. I originally came to VDRM because they pumped their product as a killer niche product for diabetic foot problems that had no end game but amputation. Not only could they heal sores, the medicine was good enough to allow doctors to save even the worst cases from amputation. No other med on the market could do that- a killer niche for a small company in a fairly large market. Chris went to conferences with diabetes doctors and concentrated on that market. Now that emphasis seems to be forgotten. Either the pump about the product was BS, or IMO, a dumb decision was made to start out in the big world of topical first aid, competing against cheap competition and big companies. Microcap companies compete best in niches, where their breakthrough IP can get real traction and immediate acceptance, without getting crushed in a commodity market. Lack of transparency on this can be intentional, if the product didnt work as advertised, or VDRM has a lack of focus with what they initially intended.

In regard to the $5MM market cap and dilution, consider that the
company has issued and sold 236+ million shares in a little over a year with no increase in revenues. That is more than the entire O/S of the company prior to 10/1/2016. We can estimate the proceeds they received or gave away as employee bonuses- using IMO
a conservative level of the current price as an average (.0119)=
236,000,000 x .0119= $2,808,400. Almost $3,000,000 received by the VDRM food chain, by a company with a $5,000,000 market cap. You would have to look real hard to find another situation that is similar. In fact, only 18% of similar biotechs in a recent index of companies which includes VDRM, have an O/S of over 200 million. VDRM has diluted that much in a little over a year. If you missed either of these risks, consider them along with your positives. These are my 2 most vexing problems here that keep me from buying more, even at these levels. Anyone with a "core" or "all in" mentality here need to consider these 2 issues along with your
views. All IMO, of course.